TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24265734

Group type: EXPERIMENTAL
Intervention: Active office (n = 19)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Active Workstation and promotion of incidental office activity
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Traditional physical activity (n = 14)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Office ergonomics (n = 29)
Number of subjects: 62
Study: 21517170

Group type: EXPERIMENTAL
Intervention: Telic state (n = 22)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Paratelic state (n = 33)
Number of subjects: 55
Study: 18512710

Group type: EXPERIMENTAL
Intervention: Rituximab (1,000 mg on days 1 and 15)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17023704

Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g) plus alpha-tocopherol (800 IU)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 14622640

Group type: EXPERIMENTAL
Intervention: Secondary prevention clinic attendance
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Self-reported data from interviews
Number of subjects: 179
Study: 11271082

Group type: EXPERIMENTAL
Intervention: Pressure-time curve (P-T) with minimum flow delay
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pressure-time curve (P-T) with maximum flow delay
Number of subjects: 11

Group type: COMPARATOR
Intervention: Pressure-volume curve (P-V)
Number of subjects: 11
Study: 9074381

Group type: EXPERIMENTAL
Intervention: Competency-based trauma teaching program
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (n = 127) taught by discipline-based lectures
Number of subjects: 67
Study: 8400756

Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms/kg
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 3518646

Group type: EXPERIMENTAL
Intervention: Topical hypothermia with cold potassium cardioplegia (group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Topical hypothermia with local interruption of the coronary circulation (group 2)
Number of subjects: 100
Study: 31078666

Group type: EXPERIMENTAL
Intervention: Exenatide 10 µg twice-daily
Number of subjects: 54

Group type: COMPARATOR
Intervention: Titrated insulin glargine (iGlar)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 54
Study: 28523391

Group type: EXPERIMENTAL
Intervention: SRP plus low-level diode laser (630-670 nm, 1.875 J/cm2) for five consecutive days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SRP plus low-level diode laser (630-670 nm, 1.875 J/cm2) for ten consecutive days
Number of subjects: 60

Group type: COMPARATOR
Intervention: SRP (scaling and root planing)
Number of subjects: 60
Study: 26219568

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 316

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 316
Study: 23689954

Group type: EXPERIMENTAL
Intervention: Exchange Reamed Nailing (ERN)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Augmentation Compression Plating (ACP)
Number of subjects: 48
Study: 21244590

Group type: EXPERIMENTAL
Intervention: Osteopathy treatment (specific dosage and duration not mentioned)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Consultation with parents about trial design
Number of subjects: 20
Study: 19631303

Group type: EXPERIMENTAL
Intervention: 0.4 mg GLP-2
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1.6 mg GLP-2
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 3.2 mg GLP-2
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 100
Study: 17589373

Group type: EXPERIMENTAL
Intervention: Nelfinavir
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Combined nelfinavir and efavirenz
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Zidovudine-lamivudine
Number of subjects: 157

Group type: COMPARATOR
Intervention: Didanosine-stavudine
Number of subjects: 157
Study: 14634379

Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral floroglucine‐trimetossibenzene 3 times daily
Number of subjects: 60
Study: 10735806

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg urapidil
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 3 microg/kg clonidine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg meperidine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline 0.9% (placebo)
Number of subjects: 120
Study: 8872649

Group type: EXPERIMENTAL
Intervention: CHO‐E (5.5% CHO‐electrolyte solution)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Pl (placebo)
Number of subjects: 8
Study: 1891212

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with postoperative 5-fluorouracil (5-FU)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Full-thickness filtering procedure with modified shell tamponade technique
Number of subjects: 17
Study: 6134039

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (twice-daily as single-drug therapy)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Ampicillin and chloramphenicol (given every 6 hours)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Ampicillin and chloramphenicol
Number of subjects: 78
Study: 3932361

Group type: EXPERIMENTAL
Intervention: Polyvalent Pseudomonas vaccine (three or four dose schedule)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (two dose schedule)
Number of subjects: 0
Study: 29763504

Group type: EXPERIMENTAL
Intervention: Prototype optoelectronic CA-navigation device
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 20
Study: 27614458

Group type: EXPERIMENTAL
Intervention: Omentin-1
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Osteoprotegerin (OPG)
Number of subjects: 637

Group type: COMPARATOR
Intervention: BUA levels in peri-/premenopausal women
Number of subjects: 637
Study: 24434794

Group type: EXPERIMENTAL
Intervention: Nicorandil (n = 63)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control (n = 65)
Number of subjects: 128
Study: 22626888

Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 60
Study: 20413518

Group type: EXPERIMENTAL
Intervention: Macroalbuminuria (AER >300 mg/24 h)
Number of subjects: 1439

Group type: EXPERIMENTAL
Intervention: Microalbuminuria (AER 30-300 mg/24 h)
Number of subjects: 1439

Group type: EXPERIMENTAL
Intervention: AER <30 mg/24 h
Number of subjects: 1439

Group type: EXPERIMENTAL
Intervention: Overall population with sustained eGFR <60 ml/min/1.73 m(2)
Number of subjects: 1439
Study: 18214668

Group type: EXPERIMENTAL
Intervention: Triarchic body‐pathway relaxation technique (TBRT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Music listening
Number of subjects: 19
Study: 15671968

Group type: EXPERIMENTAL
Intervention: Rapid Rhino nasal tampon
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rhino Rocket nasal tampon
Number of subjects: 40
Study: 12882849

Group type: EXPERIMENTAL
Intervention: Nurse-directed diabetes care in clinic A
Number of subjects: 504

Group type: COMPARATOR
Intervention: Usual (physician-directed) care in clinic B
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Nurse-directed care in clinic B (after 1 year)
Number of subjects: 504
Study: 11003631

Group type: EXPERIMENTAL
Intervention: Interferon alfa2a plus amantadine (100 mg twice a day for 48 weeks)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Interferon alfa2a alone (placebo)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Interferon alfa2a plus amantadine
Number of subjects: 119
Study: 8625679

Group type: EXPERIMENTAL
Intervention: Oral Appliance (OA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nasal-Continuous Positive Airway Pressure (N-CPAP)
Number of subjects: 25
Study: 1298563

Group type: EXPERIMENTAL
Intervention: Serum fructosamine in diabetic patients at the beginning of the study
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Serum fructosamine in diabetic patients at the 12th week visit
Number of subjects: 300

Group type: COMPARATOR
Intervention: Serum fructosamine in non-diabetic population
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Correlation of serum fructosamine with glycosylated haemoglobin
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Correlation of plasma glucose with fructosamine
Number of subjects: 300
Study: 6146371

Group type: EXPERIMENTAL
Intervention: Anxiolytic medication
Number of subjects: 91

Group type: COMPARATOR
Intervention: Brief counselling without anxiolytics
Number of subjects: 91
Study: 30471229

Group type: EXPERIMENTAL
Intervention: High-throughput sequencing (HTS) and Transcripts per million (TPM) expression analysis
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: RT-qPCR
Number of subjects: 11
Study: 30446231

Group type: EXPERIMENTAL
Intervention: Neutral rotation sling
Number of subjects: 36
Study: 27093778

Group type: EXPERIMENTAL
Intervention: Experimental oral gel
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Commercially available oral rinse
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Commercially available mouth spray
Number of subjects: 396

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 396
Study: 24305963

Group type: EXPERIMENTAL
Intervention: T1DM/ITx(+), with partial graft function
Number of subjects: 36

Group type: COMPARATOR
Intervention: Controls (healthy non-diabetic individuals)
Number of subjects: 36
Study: 23397817

Group type: EXPERIMENTAL
Intervention: Auditory cue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Audiotactile cue
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vibrotactile cue
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual cue
Number of subjects: 0
Study: 21041576

Group type: EXPERIMENTAL
Intervention: Osteoarthritis self-management intervention
Number of subjects: 515

Group type: COMPARATOR
Intervention: Health education (attention control)
Number of subjects: 515

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 515
Study: 18820346

Group type: EXPERIMENTAL
Intervention: School building footprint size
Number of subjects: 1566

Group type: EXPERIMENTAL
Intervention: Number of active outdoor amenities
Number of subjects: 1566
Study: 15685717

Group type: EXPERIMENTAL
Intervention: Drug A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug B
Number of subjects: 0
Study: 12091578

Group type: EXPERIMENTAL
Intervention: Simultaneous stimulation of auditory and somatosensory inputs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Auditory inputs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Somatosensory inputs
Number of subjects: 0
Study: 10593372

Group type: EXPERIMENTAL
Intervention: 0.125 mg ganirelix
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.25 mg ganirelix
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.50 mg ganirelix
Number of subjects: 45
Study: 9206242

Group type: EXPERIMENTAL
Intervention: Ganyan IV and Western medicine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ganyan IV in mice with acute liver damage
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Normal and liver damaged rats
Number of subjects: 60
Study: 1831630

Group type: EXPERIMENTAL
Intervention: Twice-daily oral ondansetron treatment after a single i.v. dose prechemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three times a day oral supplement regimen
Number of subjects: 0
Study: 6984358

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (200 mg) + Caffeine (100 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (200 mg) + Metoclopramide (10 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (200 mg) + Pyridoxine (300 mg)
Number of subjects: 10
Study: 31484505

Group type: EXPERIMENTAL
Intervention: Single fraction of 20.0 Gy delivered through SBRT
Number of subjects: 126

Group type: COMPARATOR
Intervention: Single fraction of 8.0 Gy delivered through three-dimensional conformal radiotherapy
Number of subjects: 126
Study: 28396221

Group type: EXPERIMENTAL
Intervention: Voice therapy (12-week protocol including vocal function exercise, hard attack, and resonance voice therapy)
Number of subjects: 19
Study: 25468590

Group type: EXPERIMENTAL
Intervention: Epidural catheter insertion with 5 mL of isotonic sodium chloride solution containing epinephrine (1:200,000)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Epidural catheter insertion with 5 mL of isotonic sodium chloride solution (control)
Number of subjects: 400
Study: 23288738

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 44
Study: 21888678

Group type: EXPERIMENTAL
Intervention: Online questionnaire
Number of subjects: 2702

Group type: EXPERIMENTAL
Intervention: Simultaneous mixed mode (paper questionnaire and login details sent together)
Number of subjects: 2702

Group type: EXPERIMENTAL
Intervention: Sequential mixed mode (online followed by a paper questionnaire with reminder)
Number of subjects: 2702

Group type: COMPARATOR
Intervention: Cost comparison
Number of subjects: 2702
Study: 19480325

Group type: EXPERIMENTAL
Intervention: Meconium staining group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other groups (no maternal risk factor, maternal hypertension, gestational diabetes, maternal smoking history)
Number of subjects: 0
Study: 18201438

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.6%
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.4%
Number of subjects: 1240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1240
Study: 15041586

Group type: EXPERIMENTAL
Intervention: Sevoflurane with nitrous oxide and epidural block
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isoflurane with nitrous oxide and epidural block
Number of subjects: 40
Study: 11317098

Group type: EXPERIMENTAL
Intervention: UPBEAT intervention
Number of subjects: 1687

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1687
Study: 9246253

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day for 3 months, then increased to 40 mg/day for non-responders at 6 months)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Fluoxetine (40 mg/day for non-responders at 6 months)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 8280820

Group type: EXPERIMENTAL
Intervention: Mineral oil (2 to 8 tablespoons twice a day for two days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pineapple-flavoured isotonic intestinal lavage solution (20 ml/kg/h for 4 hours on two consecutive days)
Number of subjects: 36
Study: 3329516

Group type: EXPERIMENTAL
Intervention: Traxanox sodium (120 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traxanox sodium (360 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traxanox sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29782218

Group type: EXPERIMENTAL
Intervention: Simulated judo match
Number of subjects: 17
Study: 29064283

Group type: EXPERIMENTAL
Intervention: Clinician-guided treatment (n = 96)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Self-guided treatment (n = 95)
Number of subjects: 191
Study: 27739380

Group type: EXPERIMENTAL
Intervention: Anti-modiolar array
Number of subjects: 64

Group type: COMPARATOR
Intervention: Peri-modiolar array
Number of subjects: 64
Study: 26075738

Group type: EXPERIMENTAL
Intervention: Online parent education program
Number of subjects: 182

Group type: COMPARATOR
Intervention: No online parent education program
Number of subjects: 182
Study: 23994459

Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression combined with radiofrequency based plasma microtenotomy (RF group, n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Arthroscopic subacromial decompression alone (ASD group, n = 40)
Number of subjects: 80
Study: 20728082

Group type: EXPERIMENTAL
Intervention: E2 (1 mg) plus drospirenone (2 mg)
Number of subjects: 40
Study: 19470807

Group type: EXPERIMENTAL
Intervention: Balance-based torso weighting (BBTW)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no weights placed)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (standard weight placement of 1.5% body weight)
Number of subjects: 36
Study: 17896305

Group type: EXPERIMENTAL
Intervention: Enrolled in the COMS PERT trial
Number of subjects: 299

Group type: COMPARATOR
Intervention: Eligible patients not enrolled in the COMS PERT trial
Number of subjects: 299
Study: 14718460

Group type: EXPERIMENTAL
Intervention: EBUS-guided TBNA
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional TBNA
Number of subjects: 200
Study: 11573708

Group type: EXPERIMENTAL
Intervention: Implantable cardiac defibrillators
Number of subjects: 997

Group type: COMPARATOR
Intervention: Antiarrhythmic drugs
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Rehospitalization for any reason
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Rehospitalization for a cardiac problem
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Rehospitalization for a noncardiac problem
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Rehospitalization for an acute coronary syndrome
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Rehospitalization for a cardiac procedure
Number of subjects: 997
Study: 9468008

Group type: EXPERIMENTAL
Intervention: Intensive dietary counselling (sodium-reduced <100 mmol/24h, potassium-enriched >75 mmol/24h, weight-reducing diet)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Chlorthalidone 25 mg/day
Number of subjects: 42
Study: 7851167

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2151274

Group type: EXPERIMENTAL
Intervention: Zoladex, 3.6 mg depot, plus flutamide, 250 mg t.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bilateral orchidectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 0
Study: 356792

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aerosol, 800 microgram daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aerosol placebo
Number of subjects: 60
Study: 31335458

Group type: EXPERIMENTAL
Intervention: eMoCA
Number of subjects: 40

Group type: COMPARATOR
Intervention: paper MoCA
Number of subjects: 40
Study: 28039321

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 1270

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1270
Study: 26124351

Group type: EXPERIMENTAL
Intervention: E-CMF (epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: E-CMF
Number of subjects: 298

Group type: COMPARATOR
Intervention: E-T-CMF (E-CMF with paclitaxel)
Number of subjects: 298
Study: 26574828

Group type: EXPERIMENTAL
Intervention: Metal clips used to fix proximal segments of stents during the perioperative period.
Number of subjects: 83

Group type: COMPARATOR
Intervention: No treatment (control group).
Number of subjects: 83
Study: 23241048

Group type: EXPERIMENTAL
Intervention: Pregabalin 300, 450 and 600 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20937978

Group type: EXPERIMENTAL
Intervention: Prompt revascularization
Number of subjects: 2368

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 2368

Group type: COMPARATOR
Intervention: Insulin provision
Number of subjects: 2368
Study: 18184631

Group type: EXPERIMENTAL
Intervention: 30 mg elemental zinc per day
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 17015057

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (0.25 mg/kg)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Low midazolam clearance (<9.5 mL x kg(‐1) x min(‐1))
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control patients (non-ONFH)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Alcohol-related ONFH patients
Number of subjects: 130
Study: 14653286

Group type: EXPERIMENTAL
Intervention: Halogen curing light in standard mode (HS)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Halogen curing light in exponential mode (HE)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LED curing light in standard mode (LS)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LED curing light in exponential mode (LE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (specimens stored in air)
Number of subjects: 45
Study: 11078841

Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy (20 Gy of 6-MV photons to the macula of the affected eye)
Number of subjects: 101

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 101
Study: 9021649

Group type: EXPERIMENTAL
Intervention: Electrodermal responses (EDR)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Skin resistance and skin conductance ohmic perturbation duration indices
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Conductance amplitude
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Skin potential responses
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Skin temperature, skin blood flow, and instantaneous respiratory frequency
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Non-oscillatory duration index values
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Skin temperature
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Instantaneous respiratory frequency perturbation duration index
Number of subjects: 6
Study: 7514156

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3371094

Group type: COMPARATOR
Intervention: Oxygen delivered by nasal prongs (3 L/min)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oxygen delivered by economizer (3 L/min)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Comparison between economizer and nasal prongs in COPD patients
Number of subjects: 16
Study: 30021626

Group type: EXPERIMENTAL
Intervention: Cocoa-based products (mean intake 618.7 mg/day)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Berries
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Green tea
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Red wine (mean intake 123.7 mg/day)
Number of subjects: 226